Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,036 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,949 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06090864 | ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells | recruiting | Phase 1 / Phase 2 | 31 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06483100 | Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance | recruiting | Phase 2 | 65 | Washington University School of MedicineOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06533579 | Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) | recruiting | Phase 1 / Phase 2 | 32 | Vironexis Biotherapeutics Inc.INDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06600568 | Novel Therapeutic Approach for Human T-cell Malignancies | recruiting | — | 120 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07024706 | Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab(MAVRiC) | recruiting | Phase 2 | 80 | AstraZenecaINDUSTRY | 8 | Aug 6, 2026 | clinicaltrials |
| NCT07249528 | A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy | recruiting | — | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07284758 | A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma(MOMENTUM) | recruiting | Phase 2 | 100 | C4 Therapeutics, Inc.INDUSTRY | 2 | Aug 6, 2026 | clinicaltrials |
| NCT07749365 | Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL | recruiting | Phase 2 | 53 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07750886 | Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)(SCORE-NHL) | recruiting | — | 200 | Natera, Inc.INDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT04906096 | Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL | recruiting | Phase 2 | 25 | Lakshmi Nayak, MDOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06116110 | Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU | recruiting | — | 150 | Miltenyi Biomedicine GmbHINDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06506643 | Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms | recruiting | Phase 1 / Phase 2 | 36 | Vector Vitale LLCINDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06669247 | A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma(COSTIMM) | recruiting | Phase 1 / Phase 2 | 186 | Regeneron PharmaceuticalsINDUSTRY | 2 | Aug 5, 2026 | clinicaltrials |
| NCT06675123 | Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma | recruiting | Phase 1 | 10 | City of Hope Medical CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06895538 | Comparison of ATLG and ATG for Immune Reconstitution After Allo-HSCT for Hematologic Malignancy | recruiting | Phase 2 / Phase 3 | 24 | Peking University First HospitalOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06940791 | Tirabrutinib Maintenance Versus Placebo in Patients With Primary CNS Lymphoma in Complete Remission (JCOG2104)(TIMELY-pII) | recruiting | Phase 2 | 92 | Kyorin UniversityOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07293403 | Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas | recruiting | Phase 2 | 25 | City of Hope Medical CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07371403 | MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia | recruiting | N/A | 12 | King Hussein Cancer CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT05170399 | Vaccine Responses in Patients With B Cell Malignancies | recruiting | Phase 4 | 350 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07188558 | A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy(PiNACLE-H2H) | recruiting | Phase 3 | 400 | Lyell Immunopharma, Inc.INDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT06760052 | Longitudinal Data Registry of Plasma Cell Dyscrasia | recruiting | — | 2,000 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT06960993 | Mosaic Trial for Stem Cell Transplant Recipients(Mosaic) | recruiting | N/A | 356 | Northwestern UniversityOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07634653 | Strength Training Exercise in Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (STEP-ALL)(STEP-ALL) | recruiting | N/A | 40 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07638683 | A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL). | recruiting | Phase 2 | 30 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07742215 | A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)(AMMADINA) | recruiting | Phase 3 | 390 | BiocadINDUSTRY | 2 | Aug 3, 2026 | clinicaltrials |
| NCT01804686 | A Long-term Extension Study of PCI-32765 (Ibrutinib)(CAN3001) | recruiting | Phase 3 | 700 | Janssen Research & Development, LLCINDUSTRY | 30 | Jul 31, 2026 | clinicaltrials |
| NCT03011814 | Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 78 | City of Hope Medical CenterOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT06708897 | A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies | recruiting | Phase 1 | 84 | Lomond Therapeutics Holdings, Inc.INDUSTRY | 1 | Jul 31, 2026 | clinicaltrials |
| NCT06965114 | Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia | recruiting | Phase 1 / Phase 2 | 84 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07069699 | Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene | recruiting | Phase 1 / Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07117136 | Blinatumomab Consolidation in Real World | recruiting | — | 200 | Medical College of WisconsinOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07628634 | Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors | recruiting | Early Phase 1 | 25 | University of California, IrvineOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT02727803 | Personalized NK Cell Therapy in CBT | recruiting | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT06785818 | Long-term Follow up Local Registry Study of Kymriah in South Korea | recruiting | — | 500 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 30, 2026 | clinicaltrials |
| NCT06967610 | Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). | recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07197307 | Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)(CLEAR) | recruiting | Phase 2 | 120 | Universität MünsterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07424833 | A Study of APG-3288 in Relapsed/Refractory Blood Cancers | recruiting | Phase 1 | 180 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Jul 30, 2026 | clinicaltrials |
| NCT07609862 | A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies | recruiting | Phase 1 / Phase 2 | 92 | Guangzhou Lupeng Pharmaceutical Company LTD.INDUSTRY | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07652281 | A Clinical Study of SHR-5421 in Patients With Multiple Myeloma | recruiting | Phase 1 | 97 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 30, 2026 | clinicaltrials |
| NCT05357794 | Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides | recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT05365659 | IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas | recruiting | Phase 1 | 140 | Iksuda Therapeutics Ltd.INDUSTRY | 5 | Jul 29, 2026 | clinicaltrials |
| NCT05773040 | A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas | recruiting | Phase 1 | 33 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT05827549 | Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia(ReCALL) | recruiting | Phase 2 | 90 | Ho Joon ImOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT06184009 | Treatment of Newly Diagnosed High Risk Pediatric Acute Lymphoblastic Leukemia(HR ALL) | recruiting | Phase 2 | 370 | Jae Wook LeeOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT06257394 | Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea(VHR ALL) | recruiting | Phase 2 | 74 | Hyoung Jin KangOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT06516679 | Efficacy of Risk-Stratified Treatment in Newly Diagnosed Infant Leukemia | recruiting | Phase 2 | 40 | Yonsei UniversityOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07397832 | CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL | recruiting | Phase 2 | 58 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07730515 | Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 176 | Evopoint Biosciences Inc.INDUSTRY | 1 | Jul 29, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 6, 2026source: clinicaltrials